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Abstract: Previous work from our group has shown that Cd38−/− mice develop a milder
pristane-induced lupus disease than WT or Art2−/− counterparts, demonstrating a new role for
CD38 in promoting aberrant inflammation and lupus-like autoimmunity via a Transient Receptor
Potential Melastatin 2 (TRPM2)-dependent apoptosis-driven mechanism. In this study we asked
whether CD38 may play a role in the expression and function of regulatory B cells (IL-10-producing
B cells or B10 cells). In pristane-treated mice the frequency of spleen CD19+CD1dhiCD5+ B cells,
which are highly enriched in B10 cells, was significantly increased in Cd38−/− splenocytes compared
to WT, while the frequency of peritoneal plasmacytoid dendritic cells (pDCs), which are major type I
Interferon (IFN) producers, was greatly diminished. The low proportion of pDCs correlated with
lower amounts of IFN-α in the peritoneal lavage fluids of the Cd38−/− mice than of WT and Art2−/−
mice. Functional ex vivo assays showed increased frequencies of IL-10-producing B cells in Cd38−/−
splenocytes than in WT upon stimulation with an agonist anti-CD40 mAb. Overall these results
strongly suggest that Cd38−/− mice are better suited than WT mice to generate and expand regulatory
B10 cells following the appropriate stimulation.
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1. Introduction
CD38 is a transmembrane glycoprotein with receptor-mediated signaling capabilities and is
an enzyme that catalyzes nicotinamide adenine dinucleotide (NAD+) or nicotinamide adenine
dinucleotide phosphate (NADP+) to produce molecules involved in Ca2+ messenger signaling
(cyclic ADPR (cADPR), adenosine diphosphate ribose (ADPR), and nicotinic acid adenine dinucleotide
phosphate (NAADP). Previous studies of our group in Systemic Lupus Erythematosus (SLE) patients
show increased CD38 surface expression in T cells and low levels of anti-CD38 autoantibodies in
clinically active patients. Furthermore, increased CD38 expression in SLE B cells correlated exclusively
with plasma levels of IL-10 [1]. Other results from our group show that IL-10 gene expression in
SLE patients correlates with CD38 gene expression; moreover, CD38 expression correlates with AKT
serine/threonine kinase 1 (AKT1) expression [2], and in human T and B cells CD38 receptor stimulation
leads to Protein Kinase B (PKB)/AKT and Extracellular signal-Regulated protein Kinase (ERK)
activation [3]. In a kinase-dead mutant of PI3Kp110δ mice, Patton et al. [4] reported that PI3Kp110δ
kinase regulates expression of CD38 on regulatory T cells (Treg). These studies, combined with
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the observations that continuous administration of anti-IL-10 demonstrated a delay in onset of
autoimmunity in NZB/W F1 mice [5], and anti-IL-10 mAb administered to six steroid-dependent
patients with SLE was shown to have a beneficial effect on disease activity [6], suggest that this
cytokine may promote disease. Other studies in IL-10 gene-deficient (IL-10−/−) MRL-Faslpr (MRL-Faslpr
IL-10−/−) mice, however, suggest that IL-10 may play a suppressive role in lupus [7]. As suggested by
others, these contradictory findings are most likely explained by the fact that multiple cell types are
capable of producing IL-10, including B cells. Therefore, the positive and negative regulatory roles of
IL-10 are likely to differ depending on the cell source of IL-10, as well as the timing of its production,
duration, and levels of IL-10 expression [8].
Furthermore, Blair et al. [9] documented that human CD19+CD24hiCD38hi B cells exhibit
regulatory capacity in healthy individuals, while the same B cells from SLE patients produced less
IL-10 and lacked the suppressive capacity. Our data showed an increase in FOXP3-(Treg) gene
expression in SLE patients that positively correlated with IL-10 gene expression [2]. Mouse regulatory
B cells (IL-10-producing B cells or B10 cells) control T-cell autoimmunity through IL-21-dependent
cognate interactions [10,11]. B10 cells are highly enriched in the spleen within the CD1dhiCD5+ B cell
subset [12,13]. Prophylactic B cell depletion by repeated CD20 mAb treatments prolonged survival
during pristane-accelerated lupus in NZB/W F1 mice, and also delayed spontaneous disease in
NZB/W F1 mice. In contrast, B cell depletion initiated in 4-week-old mice hastened disease onset,
which paralleled depletion of the B10 cells [14]. Note that the pathologic manifestations of nephritis
appear significantly earlier, and survival is significantly reduced in NZB/W F1 mice that lack B10
cells because of constitutive CD19-deficiency [8]. In this study, CD19 deficiency led to lower serum
IL-10 levels in NZB/W mice throughout the disease course. The transfer of splenic CD1dhiCD5+ B
cells from wild type NZB/W F1 mice into CD19−/− NZB/W F1 recipients significantly prolongs their
survival [8]. Thus, B10 cell IL-10 production is but one component of a complex regulatory network
that balances protective and pathogenic immune responses [15].
IL-10 seems to be involved in inhibiting some of the clinical/pathologic manifestations of
pristane-induced lupus such as diffuse alveolar hemorrhage (DAH) [16]. Although the mechanism
is still not fully understood, it seems that IL-10 protects against pristane-induced lung injury by
interacting with IL-10R on alveolar macrophages or bone marrow-derived cells [16]. Cd38−/− mice
develop a milder pristane-induced lupus disease than WT and Art2−/− mice [17]. Our data
demonstrate that CD38 promotes pristane-induced chronic inflammation and increases susceptibility
to experimental lupus by an apoptosis-driven and Transient Receptor Potential Melastatin 2
(TRPM2)-dependent mechanism [17]. On the other hand, NAD-induced cell death (NICD), which acts
through the mono-ADP-ribosyltransferase 2(ART2)-P2X purinoreceptor 7 (P2X7) pathway [18,19],
is regulated by CD38. Indeed, lack of CD38 in ART2+ T cells results in increased NICD, which correlates
with a significant reduction in Tregs and immunoregulatory natural killer T (iNKT) cells, even under
steady-state conditions [20]. Depending on the involved apoptotic T-cell subset, enhanced ART2
activity could result in immunosuppression or autoimmunity. For that reason, we have reported
that lack of CD38 in a B6 genetic background ameliorates autoimmunity in the collagen-induced
arthritis model due to decreased iNKT cells in secondary lymphoid organs that were unable to
boost a Type 1 helper T cell (Th1) response [21]. Note that IL-10-producing NKT (NKT10) cells that
resemble type 1 regulatory T cells have also been characterized [22]. Through the production of IL-10,
αGalCer-pretreated iNKT cells impaired antitumor responses and reduced disease in experimental
autoimmune encephalomyelitis, a mouse model of autoimmune disease [22].
We asked whether CD38 may play a role in Breg expression and function. To answer this question
we investigated whether there were differences in Breg expression and function between WT and
CD38-deficient mice in naïve mice. Also, we provide data on the frequencies of the CD1dhiCD5+ B cell
subset, plasmacytoid dendritic cells (pDCs), and peritoneal levels of IFN-α in the pristane-induced
lupus disease model.
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2. Results
2.1. Similar Proportion of Splenic CD1dhiCD5+ B Cells in Naïve Cd38−/− and WT Mice
Since spleen regulatory B10 cells are highly enriched within the CD1dhiCD5+ B cell subset [12],
we first assessed the frequency of these cells in naïve Cd38−/− and WT mice. As shown in Figure 1,
naïve Cd38−/− mice showed a similar proportion of CD1dhiCD5+ B cells than in WT mice.
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B cell subsets. The mean frequencies ± SEM of the CD1dhiCD5+ cells are highlighted. (b) Frequencies ± 
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and dots represent the individual values per mouse. Graph summarizes the results from nine 
independent experiments with a total of nine WT mice and eight Cd38−/− mice. 
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defined by the CD1d and CD5 markers. As shown in Figure 2, CD38 expression was significantly 
higher in the CD1dhi subsets, either CD5+ or CD5− than in the other two subsets. Note that the highest 
CD38 expression resides in the CD1dhiCD5+ subset; as these differences are statistically significant 
they confirm and extend previous results obtained by others [23]. 
Figure 1. Similar proportion of splenic CD1dhiCD5+ B cells in naïve Cd38−/− and WT mice. Spleen cells
were stained for cell su face CD1d, CD5, CD38, and CD19 as described in Material and M thods.
Gating strategy is shown in Figure S1. (a) Representative contour-plots of CD1d and CD5 expression
by CD19+ B cell fr m WT and Cd38−/− mice. Q1–Q4 quad ants show the frequencies of the
four major B cell subsets. The mean frequencies ± SEM of the CD1dhiCD5+ cell are highlighted.
(b) Frequencies ± SEM of the CD1dhiCD5+ (left) and CD1dloCD5− (rig t) B cells. Bars repres t the
mean frequencies and dots represent the individual values per mouse. Graph summarizes the r sults
from nine independent experiments with a total of nine WT mice and eight Cd38−/− mice.
2.2. Increased Surface Expression of CD38 in WT CD1dhiCD5+ B Cell Subset
I creased CD38 su face expression is a hallmark of regulatory B cells in both human and
mice [9,23]. Therefore, we tested CD38 surface expression in the four major B cells subsets (CD19+
cells) defined by the CD1d and CD5 markers. As shown in Figure 2, CD38 expression was significantly
higher in the CD1dhi subsets, either CD5+ or CD5− than in the other two subsets. Note that the highest
CD38 expression resides in the CD1dhiCD5+ subset; as these differences are statistically significant
they confirm and extend previous results obtained by others [23].
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Figure 2. Increased surface expression of CD38 in WT CD1dhiCD5+ B cells. (a) Histograms represent 
CD38 expression determined by flow cytometry in each gated B cell subset from Figure 1a. Numbers 
within each panel represent the mean fluorescence intensities (MFI) for CD38 of a representative 
experiment performed in parallel in a naïve WT (upper panels) and in a naïve Cd38−/− mouse. (b) 
Mean ± SEM of MFIs for CD38 expression in the four B cell subsets from spleens of WT and Cd38−/− 
mice. Graph summarizes the results from nine independent experiments with a total of nine WT 
mice and eight Cd38−/− mice. **** p < 0.0001; Ordinary One-Way ANOVA test corrected using Tukey’s 
multiple comparisons test. 
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Since reduced numbers and/or functions of iNKT cells have been shown to exacerbate 
pristane-induced lupus nephritis [24], we assessed whether the absence of ART2 or CD38 had any 
influence on the frequency of CD1dhiCD5+ B cells in the spleen of mice treated with pristane. In 
pristane-treated mice, the frequency of CD1dhiCD5+ B cells was significantly higher in Cd38−/− than in 
WT and Art2−/− mice (Figure 3). Note that B10 cells are particularly enriched within the CD1dhiCD5+ 
subset, where they represent 15–20% of the cells of this subset in C57BL/6 mice [25]. Together with 
this increased frequencies in CD1dhiCD5+ B cells, a significant increase of CD1d expression on these 
cells was detected in diseased Cd38−/− mice (fluorescent mean intensity (FMI) = 475 ± 10.2, n = 5) as 
compared to WT mice (FMI = 399.8 ± 7.7, n = 5, p = 0.0014) and diseased Art2−/− mice (FMI = 369.4 ± 
13.1, n = 5, p < 0.0001). These results resemble the observed upregulation of CD1d on MLN B cells 
from mice under a chronic intestinal inflammatory condition, which produced IL-10, and 
suppressed progression of intestinal inflammation [26]. 
Figure 2. Increased surface expression of CD38 in WT CD1dhiCD5+ B cells. (a) Histograms
represent CD38 expression determined by flow cytometry in each gated B cell subset from Figure 1a.
Numbers within each panel represent the mean fluorescence intensities (MFI) for CD38 of a
representative experiment performed in parallel in a naïve WT (upper panels) and in a naïve Cd38−/−
mouse. (b) Mean ± SEM of MFIs for CD38 expression in the four B cell subsets from spleens of WT
and Cd38−/− mice. Graph summarizes the results from nine independent experiments with a total of
nine WT mice and eight Cd38−/− mice. **** p < 0.0001; Ordinary One-Way ANOVA test corrected using
Tukey’s multiple comparisons test.
2.3. Increased Frequency of CD1dhiCD5+ B Cells in Spleen from Pristane-treated Cd38−/− Mice
Since reduced numbers and/or functions of iNKT cells have been shown to exacerbate
pristane-induced lupus nephritis [24], we assessed whether the bsenc of ART2 or CD38 h d
any influe ce on the frequency of CD1dhiCD5+ B cells in the spleen of mice treated with pristane.
I pristane-treated mice, the frequency of CD1dhiCD5+ B cell was significantly higher in Cd38−/− tha
in WT and Ar 2−/− mice (Figure 3). Note that B10 cells are particularly enriched wit in the CD1dhiCD5+
subset, where they represent 15–20% of the cells of this subset in C57BL/6 mice [25]. Together with
this increased fr qu ncies in CD1dhiCD5+ B cells, a ignificant increase of CD1d expr ssion on
t e e cells was detected in diseased Cd38−/− mice (fluorescent mean intensity (FMI) = 475 ± 10.2,
n = 5) as compared to WT mice (FMI = 399.8 ± 7.7, = 5, p = 0.0014) and diseased Art −/− mice
(FMI = 369.4 ± 13.1, n = 5, p < 0.0001). These results resemble the observed upregulation of CD1d on
MLN B cells from mice und r a chronic intestinal inflammatory condition, which produced IL-10,
and suppr ssed progression of intestinal inflam ation [26].
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CD19+-gated B cells of a representative experiment are shown. In quadrant Q2, the percentages ± 
SEM of CD1dhiCD5+ B cells are highlighted. (b) Bars represent mean ± SEM of frequencies of 
CD1dhiCD5+ B cells (left panel), and CD1dloCD5- B cells (right panel) in spleen of WT, Cd38−/−, and 
Art2−/− mice injected i.p. with pristane 2 weeks before. Each dot represents the value from 1 distinct 
mouse (n = 5 mice per group). * p = 0.0203; ** p = 0.0022. Unpaired t-test. The results are representative 
of at least two independent experiments. 
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showed reduced autoantibody, type I IFN signature, and kidney pathology compared to WT and 
Art2−/− mice [17]. 
Figure 3. Increased frequency of CD1dhiCD5+ B cells in spleen from pristane-treated Cd38−/− mice.
(a) Spleen cells from 2-week pristane-treated mice were stained with anti-CD19-Allophycocyanin (APC),
anti-CD38-Fluorescein isothiocyanate (FITC), anti-CD5-Peridinin-chlorophyll-protein complex (PerCP),
and anti-CD1d-Phycoerythrin (PE) mAbs. Contour-plots of CD1d vs. CD5 of CD19+-gated B cells of
a representative experiment are shown. In quadrant Q2, the percentages ± SEM of CD1dhiCD5+ B
cells are highlighted. (b) Bars represent mean ± SEM of frequencies of CD1dhiCD5+ B cells (left panel),
and CD1dloCD5− B cells (right panel) in spleen of WT, Cd38−/−, and Art2−/− mice injected i.p.
with pristane 2 weeks before. Each dot represents the value from 1 distinct mouse (n = 5 mice per
group). * p = 0.0203; ** p = 0.0022. Unpaired t-test. The results are representative of at least two
independent experiments.
2.4. Decreased Percentages of Plasmacytoid Dendritic Cells (pDCs) and Diminished IFN-α Secretion in
Peritoneal Lavag Fluids of Prist ne-Treate Cd38−/− Mice
In the pristane lupus model, we also tested whether the frequency of pDCs and IFN-α production
was compromi ed in Cd38−/− mice. As shown in Figur 4a,b, the frequencies of pDCs were
significantly redu ed in peritoneal exudate cells (PECs) from pristane-treated Cd38−/− mice. In contrast,
no significant diffe nces were observed in the fr quencies of pDCs in spleen c lls of these mice
(Figure 4b). The low proportion of pDCs correlated with lower am unts of IFN-α detected in the
peritoneal lavage fluids f the Cd38−/− mice as compared with t at in WT and Art2−/− mice (Figur 4c).
Indeed, these d ta are in agreem nt with our previous study where pristane-treated Cd38−/− mice
showe reduc d autoantibody, type I IFN signatur , and kidney pathology comp r to WT and
Art2−/− mice [17].
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Figure 4. Decreased percentages of plasmacytoid dendritic cells (pDCs) and diminished IFN-α 
secretion in peritoneal lavage fluids of pristane-treated Cd38−/− mice. (a) Two weeks after pristane i.p. 
injection, spleen cells and peritoneal exudate cells (PECs) from WT, Cd38−/−, and Art2−/− mice were 
stained with anti-B220-FITC, anti-CD11b-APC, anti-Gr1-PE, and anti-CD5-PerCP mAbs. After gating 
the CD11b− cells, pseudocolor-plots of B220-FITC vs. Gr1-PE are shown. Gating strategies for PECs 
pDCs and spleen pDCs are shown in Figures S2 and S3, respectively. In Q2, percentages of pDCs are 
highlighted in a representative experiment. According with Nakano et al [27], pDCs are CD11b−, and 
double-positive for B220 and Gr1. Pseudocolor plots display the relative population density of cell 
populations within the graph window along two parameters, blue and green dots correspond to 
areas of lower cell density, red and orange are areas of high cell density, and yellow is mid-range (b) 
Mean ± SEM of percentages of PECs pDCs from 2-week-pristane treated mice. ** p = 0.0064, ordinary 
1-way ANOVA corrected with Tukey’s multiple comparisons test. (c) Mean ± SEM of pDC numbers 
in PECs from 2-week-pristane mice. * p = 0.0426. (d) Mean ± SEM of percentages of spleen pDCs from 
2-week-pristane treated mice (n = 5 mice per group). (e) Peritoneal lavage fluids were harvested form 
2week pristane-treated mice (n = 4–5 mice per group) as described in Material and Methods. IFN-α 
levels were quantified by ELISA. * p = 0.0473, **** p < 0.0001, ordinary 1-way ANOVA corrected with 
Bonferroni’s multiple comparisons test. The results are representative of at least three independent 
experiments for peritoneal pDCs and two experiments for spleen pDCs. 
2.5. Increased Frequencies of B10 + B10pro Cells in Spleen from Cd38−/− Mice 
Because IL-10 production is the hallmark of B10 cells, IL-10 secretion by spleen cells was 
investigated following a 5 h LPIB stimulation as described in Material and Methods. As shown in 
Figure 5, the proportion of IL-10-expressing B cells was higher in spleen from WT than from Cd38−/− 
mice (3.1 ± 0.37% in WT vs. 2.09 ± 0.18% in Cd38−/−, n = 7 per group), although these differences were 
not statistically significant. Note that B10 cells are phenotypically distinct although they share some 
overlapping phenotypic markers with other regulatory B cells subsets, including the transitional-2 
(T2)-Marginal Zone (MZ) precursor B cells [25], which are highly positive for CD38 expression in 
WT mice, and show decreasing frequencies in Cd38−/− splenocytes [28]. 
B10 progenitor (B10pro) cells have also been identified within the spleen CD1dhiCD5+CD19hi 
B-cell subset [13]. B10 pro cells are defined as those B cells that are not induced to express 
cytoplasmic IL-10 after LPIB stimulation for 5 h, but that can be induced to mature into IL-10 
Figure 4. Decreased percentages of plasmacytoid dendritic cells (pDCs) and diminished IFN-α secretion
in peritoneal lavage fluids of pristane-treated Cd38−/− mice. (a) Two weeks after pristane i.p. injection,
spleen cells and peritoneal exudate cells (PECs) from WT, Cd38−/−, and Art2−/− mice were stained with
anti-B220-FITC, anti-CD11b-APC, anti-Gr1-PE, and anti-CD5-PerCP mAbs. After gating the CD11b−
cells, pseudocolor-plots of B220-FITC vs. Gr1-PE are shown. Gating strategies for PECs pDCs and
spleen pDCs are shown in Figures S2 and S3, respectively. In Q2, percentages of pDCs are highlighted in
a representative experiment. According with Nakano et al [27], pDCs are CD11b−, and double-positive
for B220 and Gr1. Pseudocolor plots display the relative population density of cell populations within
the graph window along two parameters, blue and green dots correspond to areas of lower cell density,
red and orange are areas of high cell density, and yellow is mid-range (b) Mean ± SEM of percentages
of PECs pDCs from 2-week-pristane treated mice. ** p = 0.0064, ordinary 1-way ANOVA corrected with
Tukey’s multiple comparisons test. (c) Mean ± SEM of pDC numbers in PECs from 2-week-pristane
mice. * p = 0.0426. (d) Mean ± SEM of percentages of spleen pDCs from 2-week-pristane treated mice
(n = 5 mice per group). (e) Peritoneal lavage fluids were harvested form 2week pristane-treated mice
(n = 4–5 mice per group) as described in Material and Methods. IFN-α levels were quantified by ELISA.
* p = 0.0473, **** p < 0.0001, ordinary 1-way ANOVA corrected with Bonferroni’s multiple comparisons
test. The results are representative of at least three independent experiments for peritoneal pDCs and
two experiments for spleen pDCs.
2.5. Increased Frequencies of B10 + B10pro Cells in Spleen from Cd38−/− Mice
Because IL-10 production is the hallmark of B10 cells, IL-10 secretion by spleen cells was
investigated following a 5 h LPIB stimulation as described in Material and Methods. As shown
in Figure 5, the proportion of IL-10-expressing B cells was higher in spleen from WT than from Cd38−/−
mice (3.1± 0.37% in WT vs. 2.09± 0.18% in Cd38−/−, n = 7 per group), although these differences were
not statistically significant. Note that B10 cells are phenotypically distinct although they share some
overlapping phenotypic markers with other regulatory B cells subsets, including the transitional-2
(T2)-Marginal Zone (MZ) precursor B cells [25], which are highly positive for CD38 expression in WT
mice, and show decreasing frequencies in Cd38−/− splenocytes [28].
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PMA + Ionomycin + Brefeldin A (LPIB) for 5 h (B10 cells, middle panels), or with anti-CD40 agonistic 
mAb for 48 h, with LPIB added during the last 5 h of culture (B10 + B10pro cells, right panels). Then 
cells were stained with CD19 mAb, permeabilized, and stained with IL-10 mAb for flow cytometry 
analysis. Gates show the percentages of IL-10 producing cells among total CD19+ B cells. 
Pseudocolor/smoothing/outliers plots are represented. Blue and green colors correspond to areas of 
lower cell density, red and orange are areas of high cell density, and yellow is mid-range. Outliers 
represent the lowest density of cells and are represented as black dots. (b) Bars represent the mean ± 
SEM of the percentages of IL-10+ CD19+ B cells in controls, B10 cells, and B10 + B10pro cells from WT 
splenocytes (closed bars) or Cd38−/− splenocytes (open bars). The frequency of CD19+ B cells that 
express IL-10+ increases significantly after 48 h of anti-CD40 stimulation, reflecting maturation of 
B10pro cells into IL-10 competent B10 cells. ** p = 0.0051; *** p = 0.0003; **** p <0.0001. Ordinary 
two-way ANOVA corrected using Tukey’s multiple comparisons test. The results are representative 
of at least three independent experiments. 
Figure 5. Increased frequencies of B10 + B10pro cells in spleen from Cd38−/− mice. (a) Spleen
cells from naïve WT and Cd38−/− mice were cultured with medium alone (control cells, left panels),
with LPS + PMA + Ionomycin + Brefeldin A (LPIB) for 5 h (B10 cells, middle panels), or with
anti-CD40 agonistic mAb for 48 h, with LPIB added during the last 5 h of culture (B10 + B10pro cells,
right panels). Then cells were stained with CD19 mAb, permeabilized, and stained with IL-10 mAb
for flow cytometry analysis. Gates show the percentages of IL-10 producing cells among total CD19+
B cells. Pseudocolor/smoothing/outliers plots are represented. Blue and green colors correspond
to areas of lower cell density, red and orange are areas of high cell density, and yellow is mid-range.
Outliers represent the lowest density of cells and are represented as black dots. (b) Bars represent the
mean ± SEM of the percentages of IL-10+ CD19+ B cells in controls, B10 cells, and B10 + B10pro cells
from WT splenocytes (closed bars) or Cd38−/− splenocytes (open bars). The frequency of CD19+ B cells
that express IL-10+ increases significantly after 48 h of anti-CD40 stimulation, reflecting maturation of
B10pro cells into IL-10 competent B10 cells. ** p = 0.0051; *** p = 0.0003; **** p <0.0001. Ordinary two-way
ANOVA corrected using Tukey’s multiple comparisons test. The results are representative of at least
three independent experiments.
B10 progenitor (B10pro) cells have also been identified within the spleen CD1dhiCD5+CD19hi
B-cell subset [13]. B10 pro cells are defined as those B cells that are not induced to express cytoplasmic
IL-10 after LPIB stimulation for 5 h, but that can be induced to mature into IL-10 competent B10 cells
by ex vivo culture with agonistic CD40 mAb stimulation for 48 h [28]. Because there is not a specific
marker for B10pro cells, and IL-10 expression is the defining marker for B10 cells, it was not possible to
discriminate between B10 and B10pro cells after this 48 h ex vivo culture [29]. Therefore, we asked
whether in Cd38−/− spleen cells CD40-mediated signals may induce B10pro-cell acquisition of IL-10
competence to distinct levels than in WT. As shown in Figure 5, significant increased frequencies of
IL-10+ CD19+ B cells were observed upon stimulation with an agonist anti-CD40 mAb (48 h) + LPIB
(5 h) in Cd38−/− than in WT splenocytes. Therefore, the CD40-mediated signaling pathways seemed to
be more effective in Cd38−/− than in WT splenocytes to induce the acquisition of IL-10 competence of
the B10pro subset. Since CD40 mAb stimulation does not induce B-cell clonal expansion during the
48 h culture period [10], these results also suggest that in the absence of CD38 the frequency of B10pro
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cells might be higher than in WT mice, and CD40 agonist stimulation underscores it. The contribution
of IL-21 to the expansion of IL-10-producing B10 cells cannot be discarded [10], since unpurified
splenocytes containing T cells were used in this assay, although we have not tested this possibility.
3. Discussion
The major finding of our study is that in naïve mice the frequencies of CD5+CD1dhiCD19+ B cells
were similar in Cd38−/− and WT mice, while upon in vivo treatment with pristane, the proportion
of these cells augmented significantly in Cd38−/− mice. Since B10 cells, which strongly controls T
cell-mediated inflammatory responses, are highly enriched within the CD5+CD1dhiCD19+ B cell
subset [12], this data may reflect increased frequency and number of B10 cells in pristane-treated
Cd38−/− mice, which further suggests better in vivo capabilities to expand IL-10-producing B cells in
the absence of CD38. The functional ex vivo assays showing increased frequencies of IL-10-producing
B cells in Cd38−/− splenocytes than in WT upon stimulation with an agonist anti-CD40 mAb are
in agreement with the in vivo experiments in the pristane-induced lupus model. Since this does
not occur under steady-state conditions (naïve mice), or short-term pharmacological stimulation
(LPS + PMA + Ionomycin), these results strongly suggest that Cd38−/− mice are better suited than WT
mice to generate regulatory B10 cells under strong inflammatory conditions, or under the appropriate
agonist stimulation.
Another major finding in this study is based on the observation that naïve CD38-deficient
mice show similar frequencies of IL-10-producing B cells upon treatment of spleen cells with LPIB
treatment, which functionally defines the so-called B10 cells. Our results confirm and extend
previous data obtained by Domínguez-Pantoja and colleagues, which showed decreased proportion of
CD5+CD1dhiCD19+ B cells in naïve Cd38−/− mice, whereas the proportion of IL-10-producing cells
within this B cell subset was similar to that in WT [23]. It is interesting to note that these authors tested
the frequencies of CD5+CD1dhiCD19+ B cells upon 48 h in vitro culture with either medium alone or
in the presence of LPS (48 h) and PIM (5 h), while we tested that in freshly isolated spleen cells from
naïve mice or pristane-treated mice. Secondly, our functional data on IL-10 production were obtained
in cells that were stimulated with LPS for short periods of time (5 h), after treatment with an anti-CD40
mAb (48 h in total), or without anti-CD40 pre-treatment, while their procedure always involved LPS
stimulation for 48 h. It is known that the latter treatment induces strong proliferation of B10pro and
B10 cells, while anti-CD40 stimulation induces maturation of B10pro cells into IL-10 competent B10
cells, with minimal effect on proliferation and expansion of these cells [10]. Therefore, our method
allowed us to determine both B10 cell and B10pro + B10 cell numbers individually, and to observe
important differences in B10 cell frequencies relative to B10pro + B10 cell frequencies, while theirs
did not. Therefore, differences in the methodological approaches may lead to divergent results. Thus,
we report that 48 h treatment of spleen cells with a CD40 agonistic mAb induces a stronger IL-10
response in Cd38−/− than in WT. Since this treatment induces the maturation of B10pro to B10 cells
without inducing cell proliferation, these results strongly suggest that in spleen cells from Cd38−/−
mice the proportion of B10pro is higher than that in WT mice. Alternatively, we cannot discard that
Cd38−/− spleen B cells respond better to CD40 engagement due to increased signaling capabilities via
IL-21 production by T cells and CD40-CD40L interactions of B10 cells with T cells as compared with
WT counterparts. The increased capability of CD40 engagement to induce the maturation of B10pro
into IL-10 producing B cells in Cd38−/− mice is indeed in agreement with the concept that B10-cell
maturation into functional IL-10-secreting effector cells requires CD40-dependent cognate interactions
with T cells [10].
One possible explanation for the results of increased frequencies of CD5+CD1dhiCD19+ B cells
in the context of the pristane lupus model has to do with the low proportion and numbers of
peritoneal pDCs, and the decreased levels of IFN-α in Cd38−/− mice 2 weeks after pristane treatment
(Figure 4). Our working hypothesis is that in pristane-treated Cd38−/− mice the low number of pDCs,
and decreased production of IFN-α, in a relatively mild inflammatory environment, may facilitate
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the maturation of B10pro into IL-10-producing B10 cells. The increased production of IL-10 may
help to further decrease the IFN-α release. Although we do not know at this point whether this
mechanism operates in the pristane-induced lupus model, there is strong indirect evidence that this
could be the case. Thus, it is interesting to note that in healthy individuals, human pDCs drive the
differentiation of CD19+CD24hiCD38hi (immature) B cells into IL-10-producing CD24+CD38hi Breg cells
and plasmablasts, via the release of IFN-α and CD40 engagement. CD24+CD38hi Breg cells conversely
restrain IFN-α production by pDCs via IL-10 release. In contrast, in SLE, this cross-talk is compromised;
pDCs promote plasmablast differentiation but fail to induce Breg cells [30]. According to the authors
this is due in part to aberrant production of IFN-α in a strong inflammatory environment [30].
Whether this mechanism is fully operative in lupus mouse models requires further investigation,
however it is interesting to note that early, transient depletion of pDCs ameliorates autoimmunity in a
lupus model [31]. Indeed, we have shown in the pristane-induced lupus model that in Cd38−/− mice
there is reduced autoantibody production, type I IFN signature, and inflammatory signature compared
to WT and Art2−/− mice [17]. According to the model proposed by Menon et al. [30], the relatively low
IFN-α levels observed in Cd38−/− mice (Figure 4e) should be enough to help differentiate immature
B10pro cells into IL-10-producing B10 cells in a relatively mild inflammatory environment. In contrast,
WT and Art2−/− mice produce more IFN-α and are subjected to a stronger inflammatory environment
than Cd38−/− mice, so this process might be less efficient, hence the lower frequency of pDCs observed.
In light of these results, we propose a working model in Figure 6, which may facilitate future research
into this subject. In this sense, sorting of the CD1dhiCD5+CD38hiCD19+ subset and adoptive transfer
experiments would provide further insights on the role of regulatory B10 cells in the pristane lupus
model. Alternatively, the ex vivo expansion and reinfusion of autologous B10 cells strategy, which has
been successfully used in other autoimmune diseases [10], may provide an effective in vivo treatment
for this mouse model of SLE.
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4. Materials and Methods
4.1. Mice
Cd38−/− and Art2−/− mice [32,33] were backcrossed for 12 generations to the C57BL/6 J (B6)
background, bred, and maintained under specific pathogen-free conditions at the IPBLN-CSIC
Animal Facility (register No: ES-180210000022) in Granada, Spain until they were 4 weeks-old.
Wild-type C57BL/6 J mice were purchased from Charles River (Barcelona, Spain). 8–12-week-old
mice received a single dose of 0.5 mL pristane (2,6,10,14-tetramethylpentadecane [34]; Sigma-Aldrich,
Merck KGaA, Darmstadt, Germany) that was filtered through a 0.25-µm filter and administered
intraperitoneally (i.p.). Control mice received either a single dose of 0.5 mL saline or were left untreated.
Peritoneal cells, spleen, and blood were harvested 2 weeks after treatment. All experimental procedures
involving animals at IPBLN-CSIC were approved by the Institutional Animal Care and Use Committee
(Proyect SAF2011-27261, date: 14 December 2011; Project SAF-2017-89801-R, date: 24 November 2017),
which follows the ARRIVE guidelines [35] in accordance with the U.K. Animals (Scientific Procedures,
Act, 1986) and associated guidelines (EU Directive 2010/63/EU for animal experiments), and with
the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications
No. 8023, revised 1978).
4.2. Splenocytes
Spleens were obtained and placed into 3 mL of PBS/BSA/EDTA buffer (PBS, pH 7.2; 0.5% bovine
serum albumin (BSA from Sigma-Aldrich) and 2 mM EDTA (Sigma-Aldrich)) after being weighed.
The spleens were individually placed in a small petri dish between two filter papers and crushed with
the end of a syringe. The cells were then filtered through a Pre-Separation filter placed on a 15 mL
tube. 1 mL of PBS/BSA/EDTA buffer was used to wash the small petri dish and then extracted from
the petri dish to wash the Pre-Separation filter. After adding enough buffer to each tube to reach a total
volume of 10 mL, the samples were centrifuged at 1500 rpm for 5 min at 4 ◦C. After the supernatants
were removed, 1 mL of ammonium chloride solution (STEMCELL Technologies, Grenoble, France)
was used to lyse the red blood cells. The cells were then filtered through separate Pre-Separation filters
again and the Pre-Separation filters were washed with 3 mL of ammonium chloride. The cell samples
were incubated in ice for 10 min. After adding 8 mL of PBS/BSA/EDTA buffer, the cell samples were
centrifuged again at 1500 rpm for 5 min at 4 ◦C and the supernatants were removed. The cell samples
were resuspended in 1 mL of the PBS/BSA/EDTA buffer and 4 more mL of the buffer were added.
4.3. Counting
First, a 1:20 dilution was used to count each cell sample. Twenty microliters of the 1:10 diluted
cell sample and 20 µL of Trypan Blue was obtained in a micropipette and used. Ten microliters
of the total dilution was put on the plate used for counting (Neubauer hematocytometer; BRAND
GMBH + CO KG, Wertheim, Germany). The live and dead cells were counted. Calculations were
made and the appropriate number of cells was obtained from each cell sample.
4.4. Flow Cytometry
4.4.1. B Cell Subsets and pDCs
In order to analyze distinct B cell subpopulations from each of the samples,
several fluorochrome-conjugated mAb mixtures were used per experiment. For regulatory B10 cells the
mAb combination was the following: CD19-APC (clone 1D3), CD38-FITC (clone 90/CD38), CD5-PerCP
(clone 53-7.3), CD1d-PE (clone 1B1) (all from BD Biosciences, Beckton Dickinson, Franklin Lakes,
NJ, USA). For pDCs: B220-FITC (clone RA3-6B2, Biolegend, San Diego, CA, USA), CD11b-APC
(clone M1/70.15.11.5, Miltenyi Biotec, Bergisch Gladbach, Germany), Gr1-PE (clone RB6-8C5,
BD Biosciences), CD5-PerCP (clone 53-7.3, BD BioSciences). After adding the respective volumes
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of cells to two different 5 mL polystyrene (PS) tubes (Falcon, Corning, Corning, NY, USA), 2 mL of
PBS/BSA/EDTA buffer was added to each tube. The cells were centrifuged at 1500 rpm for 5 min at
4 ◦C and then the supernatants were removed. The cells were resuspended in PBS/BSA/EDTA buffer
and Mouse BD Fc Block (Rat anti-mouse CD16/CD32, clone 2.4G2, BD Biosciences) was added to
both samples. The cells incubated in ice for 20 min. The samples in the PS tubes were separated into
appropriate labeled tubes in order to add antibodies. 100 µL of PBS/BSA/EDTA was added to the
new cell separations. The antibodies were added and incubated in ice in the dark for 20 min. 2 mL of
PBS/BSA/EDTA buffer was added and centrifuged at 1500 rpm for 5 min at 4 ◦C. The supernatants
were removed. The cells were resuspended in 100 µL of PBS/BSA/EDTA buffer and 100 µL of
paraformaldehyde was added to each tube in order to fix the cells for staining.
4.4.2. Intracellular IL-10 Staining
In order to analyze the proportion of IL-10-producing B cells, spleen cells were surface stained
with an anti-CD19-APC (clone 1D3, BD Biosciences), following by permeabilization, fixation,
and intracellular staining with an anti-IL-10-PE mAb (clone JES5-16E3, Miltenyi Biotec), as previously
described [17] using the Inside Stain Kit from Miltenyi (reference 130-090-477). Briefly, after adding
the respective volumes of cells to seven (eight when using CD40 for IL-10pro stimulation) different
5 mL PS tubes, 2 mL of PBS/BSA/EDTA buffer was added to each tube. The cells were centrifuged at
1500 rpm for 5 min at 4 ◦C and then the supernatants were removed. The cells were resuspended in
PBS/BSA/EDTA buffer and centrifuged twice more. Fc Block (CD16/CD32 from BD Biosciences) was
added to all the samples. The cells incubated in ice for 20 min with foil. 100 µL of PBS/BSA/EDTA
was added to the samples. The antibody CD19-APC was added to the respective tubes and incubated
in ice in the dark for 20 min. Two microliters of PBS/BSA/EDTA buffer was added and centrifuged at
1500 rpm for 5 min at 4 ◦C. The supernatants were removed. The cells were resuspended in 100 µL of
PBS/BSA/EDTA buffer and centrifuged again. Two-hundred-and-fifty microliters of PBS/BSA/EDTA
buffer and 250 µL of Inside Fix were added to the tubes and incubated at room temperature in the
dark for 20 min. The samples were centrifuged at 1500 rpm for 5 min at 4 ◦C and the supernatant was
removed. The samples were resuspended in 1 mL of PBS/BSA/EDTA buffer, centrifuged at 1500 rpm
for 5 min at 4 ◦C and the supernatant was removed. One-hundred microliters of Inside Perm was
added to all the cells and 0.5 µL of IL-10-PE was added to the respective tubes and incubated at room
temperature for ten minutes in the dark. 1 mL of Inside Perm was added to the samples, centrifuged at
1500 rpm for 5 min at 4 ◦C and the supernatant was removed. The samples were resuspended in
200 µL of PBS/BSA/EDTA buffer.
4.4.3. Data Acquisition and Analysis
For analysis purposes, 50,000 (150,000 for functional analysis) events were acquired from each
sample using a FACSCalibur flow cytometer (BD Biosciences). The software used for data acquisition
was BD CellQuest Pro (version 0.7.df2b) and further analysis was done using the FlowJo software
(version 7.6.4, Tree Star Inc., Ashland, OR, USA). All of the data from the samples were acquired less
than 24 h from the time the samples were ready for analysis.
4.5. Functional Analysis of Regulatory B (B10) Cells
B10 cells are a functionally defined subset currently identified only by their competency to produce
and secrete IL-10 following appropriate stimulation. Therefore, the procedure described by Matsushita
and Tedder was used [29]. Briefly, splenocytes were cultured at 37 ◦C in medium alone (as a control)
containing RPMI 1640, FBS, penicillin, streptomycin, L-Glutamine, and 2-mercaptoethanol (all reagents
from GIBCO, Thermo Fisher Scientific, Waltham, MA, USA) or in culture medium containing
PMA (Sigma-Aldrich, 50 ng/mL, final concentration), ionomycin (Sigma-Aldrich, 500 ng/mL final),
LPS (Sigma-Aldrich, 10 µg/mL final), to induce IL-10 production. After 1 h incubation, Brefeldin A
(Sigma-Aldrich, 2 µg/mL final) was added to the sample with PMA, ionomycin, and LPS and cells
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were incubated for another 4 h at 37 ◦C. Then cells were stained for cell surface CD19 expression and
cytokine capture to visualize IL-10 secreting cells as described above. For analysis of B10pro and B10
cells, splenocytes were incubated in culture medium alone (as a control), or culture medium containing
the anti-CD40 mAb (Clone FGK45.5, pure-functional grade, Miltenyi, Cat No. 130-093-022, 1 µg/mL,
final) for 43 h at 37 ◦C and then another 5 h with the LPIB cocktail described above.
4.6. IFN-α ELISA
All 14 mouse IFN-α subtypes were measured using the Verikine Mouse Interferon-alpha
ELISA (PBL Assay Science, Piscataway, NJ, USA). Assays were performed according to the
manufacturer’s protocol.
4.7. Statistical Analyses
Statistical analyses were performed using the GraphPad Prism 7 software (GraphPad Software,
San Diego, CA, USA).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/10/
2906/s1.
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Abbreviations
Art2 T-cell ecto-ADP-ribosyltransferase 2
B10 IL-10-producing B cells
B10pro B10 progenitor cells
Bregs Regulatory B cells
LPIB LPS + PMA + Ionomycin + Brefeldin A
LPS Lipopolysaccharide
pDCs Plasmacytoid Dendritic Cells
PECs Peritoneal Exudate Cells
PIM PMA + Ionomycin + Monensin
PMA Phorbol 12-Myristate 13-Acetate
Pristane 2,6,10,14-Tetramethylpentadecane
SLE Systemic Lupus Erythematosus
TRPM2 Transient Receptor Potential Melastatin 2
WT Wild-Type
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